about
Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityLipid-based Transfection Reagents Exhibit Cryo-induced Increase in Transfection Efficiency.The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR ConformerInflammation-associated nitrotyrosination affects TCR recognition through reduced stability and alteration of the molecular surface of the MHC complexTriticum durum metallothionein. Isolation of the gene and structural characterization of the protein using solution scattering and molecular modeling.Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets.Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.Crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 and GP392 explain pleiotropic effects of glycosylation on antigen presentation and immunogenicity.Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome.The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 CellsEngineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transferSuccessive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin
P50
Q26773135-0F1DE848-6CF0-46A3-85AC-CCB292CDB1EEQ27317260-0D40F4E6-BB17-46DB-84D3-DDAA58EFAA1AQ27703723-50997BEC-29E9-4ADC-ACCE-5844ADC00E10Q28481493-C5156916-35F1-4432-BEF2-69CE64E6B655Q31138864-79208A87-7864-4215-BE95-4D0831DCBEBEQ33722187-DFAFC175-A778-45ED-A58C-86346DD72C5DQ33864162-B47DDC39-4B38-4ECE-AB55-2F719818CB4CQ35778422-F48B745B-A616-49EB-8BDD-9E512FB08A4DQ39694737-5F214794-29AA-4050-A6A4-DF6C89C68529Q45879904-6A651A56-08EA-416E-B83F-4E676705A5A3Q47144276-9AA9BF49-C963-45DF-B2DB-AB8B7A89C099Q51570079-CC1DB132-A1A6-44ED-98B9-3F746541671FQ52366688-660DF700-7D6F-477C-AAB8-5B7C62CF10EEQ52577558-CC25071A-9BE0-4444-8F16-4361EA1F4ADAQ61797462-F9CD1CB0-6B70-403D-B91D-1787AD61CAD0Q91756196-A08E7F05-2206-488B-AE99-23CEC8F06BCFQ91943742-C01B0DB5-048B-43B2-9F31-340C0AFA9235
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Adil Doganay Duru
@ast
Adil Doganay Duru
@en
Adil Doganay Duru
@es
Adil Doganay Duru
@nl
Adil Doganay Duru
@sl
type
label
Adil Doganay Duru
@ast
Adil Doganay Duru
@en
Adil Doganay Duru
@es
Adil Doganay Duru
@nl
Adil Doganay Duru
@sl
prefLabel
Adil Doganay Duru
@ast
Adil Doganay Duru
@en
Adil Doganay Duru
@es
Adil Doganay Duru
@nl
Adil Doganay Duru
@sl
P106
P31
P496
0000-0002-5844-913X